ERBB2 and breast carcinoma: Although there are differences in tumor biology between HER2-positive breast cancer and HER2-positive gastric cancer (GC), it was hypothesized that the dual HER2-targeted regimen could also improve survival outcomes in patients with HER2-positive advanced GC (AGC) [7].